Since the initial finding that IDH1/2 mutations induce an HDR-deficient phenotype, and therefore impaired repair of DSBs, multiple clinical trials such as NCT03749187, NCT03953898, NCT02576444, and NCT05406700 have begun evaluating the response of IDH-mutant cancers to PARPi monotherapy and combination therapy. Here, IDH1 is linked to cancer.